Tenaya Therapeutics Announces Late Breaker and New Data Presentations at the American College of Cardiology's Annual Scientific Session

Core Insights - Tenaya Therapeutics is set to present new clinical and disease burden data related to its MYBPC3-associated hypertrophic cardiomyopathy (HCM) program at the American College of Cardiology's Annual Scientific Session from March 29-31, 2025 [1][2] Company Overview - Tenaya Therapeutics is a clinical-stage biotechnology company focused on discovering, developing, and delivering potentially curative therapies for heart disease [5] - The company is advancing a pipeline that includes TN-201, a gene therapy for MYBPC3-associated HCM, TN-401 for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC), and TN-301, a small molecule HDAC6 inhibitor for heart failure with preserved ejection fraction (HFpEF) [5] Clinical Trials and Presentations - Data from the MyPEAK-1 Phase 1b/2 clinical trial will be presented, featuring one-year assessments of the first two patients who received TN-201 gene therapy, along with baseline biopsy and six-month assessments from a third patient [2] - A poster presentation will discuss findings from the Sarcomeric Human Cardiomyopathy Registry (SHaRe), highlighting differences in disease burden among adults with HCM caused by MYBPC3 mutations [3] Event Details - The presentations will take place on March 30 and March 31, 2025, at the ACC conference, with specific sessions dedicated to heart failure and cardiomyopathies [6]